Alectinib

Alectinib
Clinical data
Pronunciation/əˈlɛktɪnɪb/ ə-LEK-ti-nib
Trade namesAlecensa
Other namesalectinib hydrochloride (JAN JP)
AHFS/Drugs.comMonograph
MedlinePlusa616007
License data
Pregnancy
category
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability37% (under fed conditions)
Protein binding>99%
MetabolismMainly CYP3A4
MetabolitesM4 (active)
Elimination half-life33 hours (alectinib), 31 hours (M4)
ExcretionFeces (98%)[6]
Identifiers
  • 9-Ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
CompTox Dashboard (EPA)
ECHA InfoCard100.256.083 Edit this at Wikidata
Chemical and physical data
FormulaC30H34N4O2
Molar mass482.628 g·mol−1
3D model (JSmol)
  • CCc1cc2c(cc1N3CCC(CC3)N4CCOCC4)C(c5c(c6ccc(cc6[nH]5)C#N)C2=O)(C)C
  • InChI=1S/C30H34N4O2/c1-4-20-16-23-24(17-26(20)34-9-7-21(8-10-34)33-11-13-36-14-12-33)30(2,3)29-27(28(23)35)22-6-5-19(18-31)15-25(22)32-29/h5-6,15-17,21,32H,4,7-14H2,1-3H3 COPY
  • Key:KDGFLJKFZUIJMX-UHFFFAOYSA-N
  • Key:GYABBVHSRIHYJR-UHFFFAOYSA-N

Alectinib (INN[8]), sold under the brand name Alecensa, is an anticancer medication that is used to treat non-small-cell lung cancer (NSCLC).[6][7] It blocks the activity of anaplastic lymphoma kinase (ALK).[9][10] It is taken by mouth.[6] It was developed by Chugai Pharmaceutical Co. Japan, which is part of the Hoffmann-La Roche group.

The most common side effects include constipation, muscle pain and edema (swelling) including of the ankles and feet, the face, the eyelids and the area around the eyes.[7]

Alectinib was approved for medical use in Japan in 2014, the United States in 2015, Canada in 2016, Australia in 2017, the European Union in 2017, and the United Kingdom in 2021.[6][7]

  1. ^ a b "Australian Product Information – Alecensa (alectinib)". Guildlink.gov.au. Archived from the original on 16 May 2023. Retrieved 16 May 2023.
  2. ^ "Prescription medicines: registration of new chemical entities in Australia, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 10 April 2023. Retrieved 9 April 2023.
  3. ^ "Prescription medicines and biologicals: TGA annual summary 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 31 March 2024. Retrieved 31 March 2024.
  4. ^ "Health Canada New Drug Authorizations: 2016 Highlights". Health Canada. 14 March 2017. Archived from the original on 7 April 2024. Retrieved 7 April 2024.
  5. ^ "Alecensa 150 mg Hard Capsules Summary of Product Characteristics (SmPC)". (emc). 10 August 2023. Archived from the original on 21 August 2023. Retrieved 20 August 2023.
  6. ^ a b c d e "Alecensa- alectinib hydrochloride capsule". DailyMed. 16 June 2022. Archived from the original on 9 November 2021. Retrieved 8 January 2023.
  7. ^ a b c d "Alecensa EPAR". European Medicines Agency (EMA). 29 March 2023. Archived from the original on 13 October 2021. Retrieved 20 August 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  8. ^ World Health Organization (2013). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 70". WHO Drug Information. 27 (3). hdl:10665/331167.
  9. ^ "New Oral Therapy To Treat ALK-Positive Lung Cancer. Dec 2015". Archived from the original on 16 February 2016. Retrieved 11 February 2016.
  10. ^ McKeage K (January 2015). "Alectinib: a review of its use in advanced ALK-rearranged non-small cell lung cancer". Drugs. 75 (1): 75–82. doi:10.1007/s40265-014-0329-y. PMID 25428710. S2CID 34062880.